Nilotinib-induced autophagic changes increase endogenous parkin level and ubiquitination, leading to amyloid clearance
Open accessAbstract
Unlabelled Alzheimer's disease (AD) is a neurodegenerative disorder associated with amyloid accumulation and autophagic changes. Parkin is an E3 ubiquitin ligase involved in proteasomal and autophagic clearance. We previously demonstrated decreased parkin solubility and interaction with the key autophagy enzyme beclin-1 in AD, but tyrosine kinase inhibition restored parkin-beclin-1 interaction. In the current studies, we determined the mechanisms of nilotinib-induced parkin-beclin-1 interaction, which leads to amyloid clearance. Nilotinib increased endogenous parkin levels and ubiquitination, which may enhance parkin recycling via the proteasome, leading to increased activity and interaction with beclin-1. Parkin solubility was decreased and autophagy was altered in amyloid expressing mice, suggesting that amyloid stress affects parkin stability, leading to failure of protein clearance via the lysosome. Isolation of autophagic vacuoles revealed amyloid and parkin accumulation in autophagic compartments but nilotinib decreased insoluble parkin levels and facilitated amyloid deposition into lysosomes in wild type, but not parkin(-/-) mice, further underscoring an essential role for endogenous parkin in amyloid clearance. These results suggest that nilotinib boosts the autophagic machinery, leading to increased level of endogenous parkin that undergoes ubiquitination and interacts with beclin-1 to facilitate amyloid clearance. These data suggest that nilotinib-mediated autophagic changes may trigger parkin response via increased protein levels, providing a therapeutic strategy to reduce Aβ and Tau in AD.Key message Parkin solubility (stability) is decreased in AD and APP transgenic mice. Nilotinib-induced autophagic changes increase endogenous parkin level. Increased parkin level leads to ubiquitination and proteasomal recycling. Re-cycling decreases insoluble parkin and increases parkin-beclin-1 interaction. Beclin-1-parkin interaction enhances amyloid clearance.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
c-Abl is a tyrosine kinase whose increased activity can lead to failure of autophagic protein clearance through the lysosome, resulting in the accumulation of toxic substrates.
“c-Abl is a tyrosine kinase whose increased activity can lead to failure of auto phagic protein clearance through the lysosome, resulting in the accu mulation of toxic substrates (Abushouk et al., 2018; Lonskaya et al., 2014).”
From Nilotinib restores memory function by preventing dopaminergic neuron degeneration in a mouse model of Alzheimer’s Disease (2021) · cites this paper as Lonskaya et al., 2014
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 46 · Cited by 152
- Authors
- Lonskaya, I., Hebron, M. L., Desforges, N. M., Schachter, J. B., & Moussa, C. E.-H.
- Affiliations
- Georgetown University Medical Center (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Moussa, Charbel E-H
- Venue
- Journal of Molecular Medicine
- Published
- 2013-12-13
- Volume
- 92
- Issue
- 4
- Pages
- 373-386
- ISSN
- 0946-2716 (ISSN-L)
- 1432-1440
- PMC
- PMC3975659
- OpenAlex
- W2015808257
- Cited by
- 152
- References
- 46
- Citations by year
- 2026: 3 · 2025: 13 · 2024: 12 · 2023: 12 · 2022: 15 · 2021: 19 · 2020: 17 · 2019: 15 · 2018: 15 · 2017: 11 · 2016: 8 · 2015: 6 · 2014: 6
- FWCI
- 4.64
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Molecular Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Merck
- Georgetown University
- National Institutes of Health
- U.S. Public Health Service (30378)
- National Institute on Aging (K01AG030378)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Epidemiology › Autophagy in Disease and Therapy
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- nilotinib, Alzheimer's disease, Parkin, Beclin-1, autophagy, amyloid-beta clearance, ubiquitination, tyrosine kinase inhibition, APP transgenic mice, lysosomal clearance
- MeSH terms
- Alzheimer Disease, Amyloid, Animals, Autophagy, Enzyme Stability, Hippocampus, Humans, Male, Mice, Inbred C57BL, Mice, Transgenic, Pyrimidines, Ubiquitin-Protein Ligases, Cell Line, Tumor, Protein Kinase Inhibitors, Rats, Ubiquitination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review